Novavax said on Tuesday it signed a licensing agreement allowing Pfizer access to its technology that boosts immune ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Pharmaceutical Technology on MSN
Pfizer and Novavax ink $530m vaccine delivery licensing deal
"Pfizer and Novavax ink $530m vaccine delivery licensing deal" was originally created and published by Pharmaceutical ...
Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut ...
Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer. Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development ...
Sweeping U.S. policy changes under Health Secretary Robert F. Kennedy Jr. are having a chilling effect on vaccine makers as ...
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback